Safety Profile of Nicotinamide Riboside (NR)

Note: This information is for educational purposes only and is not intended as personalized medical advice. Consult with a healthcare provider before starting any supplement regimen.

Current Safety Evidence

The available evidence for NR safety is limited, based on a small number of clinical trials with relatively short durations. Most safety data comes from Phase 1 and early-phase studies in specific populations.

Known Side Effects

Evidence is thin regarding comprehensive side effect profiles for NR. The completed clinical trials (NCT04907110, NCT04112043) focusing on exercise enhancement and hypertensive older adults have not yet provided publicly available detailed safety data.

Common side effects reported in other NAD+ precursor studies have included:

• Gastrointestinal symptoms (nausea, stomach discomfort)
• Flushing
• Fatigue

However, specific side effect frequencies and severity for NR are not well-established in the current evidence base.

Contraindications

No specific contraindications are clearly established in the available evidence. The recruiting Phase 2 trial for atypical Parkinsonism (NCT06162013) and other studies suggest ongoing investigation in various disease states, but definitive contraindications have not been published.

Drug Interactions

Drug interaction data is extremely limited. The evidence provided does not include comprehensive interaction studies. Given NR's role as a NAD+ precursor and potential effects on cellular metabolism, theoretical interactions may exist with:

• Medications affecting cellular energy metabolism
• Cancer treatments (one suspended trial involved combination therapy)

However, specific interaction profiles require further research.

Populations That Should Exercise Caution

Based on the limited trial evidence:

Insufficient data exists for safety recommendations in:

• Pregnant or breastfeeding women
• Children and adolescents
• Individuals with severe liver or kidney disease
• Cancer patients (one cancer-related trial was suspended, though reasons are unclear)

Evidence Limitations

The safety evidence for NR is notably thin. Most trials are either ongoing, recently completed without published results, or focus on efficacy rather than comprehensive safety profiles. Long-term safety data is particularly lacking, and most studies have been conducted in relatively healthy populations or specific disease groups.

Recommendation: Given the limited safety data, individuals considering NR supplementation should consult with healthcare providers, especially those with pre-existing medical conditions or taking medications.